Aviva PLC Viking Therapeutics, Inc. Transaction History

Aviva PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$5.19 - $6.73 $1.08 Million - $1.4 Million	-207,322 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$5.74 - $9.67 $106,167 - $178,856	18,496 Added 9.8%	207,322 $1.31 Million
Q4 2020 Feb 10, 2021	SELL	$5.3 - $6.71 $811,302 - $1.03 Million	-153,076 Reduced 44.77%	188,826 $1.06 Million
Q3 2020 Nov 12, 2020	BUY	$5.73 - $8.11 $156,555 - $221,581	27,322 Added 8.69%	341,902 $1.99 Million
Q2 2020 Aug 13, 2020	SELL	$4.35 - $8.08 $1.22 Million - $2.26 Million	-280,121 Reduced 47.1%	314,580 $2.27 Million
Q1 2020 May 14, 2020	BUY	$3.45 - $7.95 $2.05 Million - $4.73 Million	594,701 New	594,701 $2.78 Million

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.18B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.